About CRESTOR

Since 2003, CRESTOR^® (rosuvastatin calcium) has been prescribed by cardiologists and health care professionals to more than 13 million patients (as of March 2008) to reduce total blood cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase high-density lipoprotein cholesterol (HDL-C).¹

In November 2007, CRESTOR was also approved to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.²

With proven efficacy in reducing LDL-C, increasing HDL-C, and slowing the progression of atherosclerosis, CRESTOR is the cholesterol medication that can help you redefine success in treating your at-risk patients.¹

Indications

CRESTOR is indicated along with diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia, and to slow the progression of atherosclerosis in adult patients, as part of a treatment strategy to lower Total-C and LDL-C to target levels.²

> See Indications for CRESTOR

CRESTOR is indicated^#

As an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia
As an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
CRESTOR is not indicated to reduce cardiovascular morbidity and mortality

CRESTOR is contraindicated^#

In patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers

Important safety information about CRESTOR^#

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir
Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol
In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^‡‡

Read full Prescribing Information (PDF - 152k)